Marshall Davenport Snavely

Title: Marshall Davenport Snavely: Innovator in Cancer Therapeutics

Introduction

Marshall Davenport Snavely is a notable inventor based in Norwalk, CT (US). He has made significant contributions to the field of cancer treatment through his innovative work on antibodies. His research focuses on the development of therapies that can improve patient outcomes in oncology.

Latest Patents

Snavely holds a patent for PD-L1 antibodies. This invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1). These antibodies may be useful for treating solid and hematological tumors, both alone and in combination with chemotherapy and other cancer therapeutics. His work in this area represents a promising advancement in cancer treatment.

Career Highlights

Snavely is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role at Eli Lilly allows him to contribute to the development of innovative therapies that address critical health challenges. His expertise in antibody development has positioned him as a key player in the fight against cancer.

Collaborations

Throughout his career, Snavely has collaborated with esteemed colleagues, including Dale Lincoln Ludwig and Yiwen Li. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic options.

Conclusion

Marshall Davenport Snavely's work in developing PD-L1 antibodies exemplifies the impact of innovation in the medical field. His contributions to cancer therapeutics highlight the importance of research and collaboration in advancing healthcare solutions.